Global Gene Therapy Market 2022-2028

December 2022 | 72 pages | ID: G47363762EECEN
Gen Consulting Company

Abstracts

According to Gen Consulting Company, the global gene therapy market is set to achieve an incremental growth of USD 11.6 billion, acelerating at a CAGR of almost 23.7% during the forecast period 2022-2028.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global gene therapy market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the gene therapy industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the indication, technology, and region. The global market for gene therapy can be segmented by indication: cancer, metabolic disorder, eye disorder, spinal muscular atrophy, others. Globally, the cancer segment made up the largest share of the gene therapy market. Gene therapy market is further segmented by technology: adeno virus vector, adeno-associated virus vector, lentiviral vector, retroviral vector, herpes virus vector, others. The adeno virus vector segment captured the largest share of the market in 2021. Based on region, the gene therapy market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. According to the research, North America had the largest share in the global gene therapy market.

Market Segmentation

By indication: cancer, metabolic disorder, eye disorder, spinal muscular atrophy, others

By technology: adeno virus vector, adeno-associated virus vector, lentiviral vector, retroviral vector, herpes virus vector, others

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report also provides a detailed analysis of several leading gene therapy market vendors that include Abeona Therapeutics Inc., Amgen Inc., Astellas Pharma Inc., Biogen, bluebird bio, Inc., Editas Medicine Inc., Generation Bio Co., Gilead Sciences Inc., Novartis AG, Orchard Therapeutics plc, REGENXBIO Inc., Roche Holding AG, Sibiono GeneTech Co., Ltd., UniQure N.V., Voyager Therapeutics Inc., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global gene therapy market.
• To classify and forecast the global gene therapy market based on indication, technology, region.
• To identify drivers and challenges for the global gene therapy market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global gene therapy market.
• To identify and analyze the profile of leading players operating in the global gene therapy market.

Why Choose This Report

• Gain a reliable outlook of the global gene therapy market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY INDICATION

Cancer
Metabolic disorder
Eye disorder
Spinal muscular atrophy
Others

PART 6. MARKET BREAKDOWN BY TECHNOLOGY

Adeno virus vector
Adeno-associated virus vector
Lentiviral vector
Retroviral vector
Herpes virus vector
Others

PART 7. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 8. KEY COMPANIES

Abeona Therapeutics Inc.
Amgen Inc.
Astellas Pharma Inc.
Biogen
bluebird bio, Inc.
Editas Medicine Inc.
Generation Bio Co.
Gilead Sciences Inc.
Novartis AG
Orchard Therapeutics plc
REGENXBIO Inc.
Roche Holding AG
Sibiono GeneTech Co., Ltd.
UniQure N.V.
Voyager Therapeutics Inc.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER